Bicara Therapeutics Grants Employees Stock Options

BOSTON, Oct. 05, 2026 /CourierPR/ -- Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing transformative bifunctional therapies for solid tumors, announced on October 1, 2026, the awarding of inducement grants to two new employees. These inducement grants were awarded as a significant inducement to employment under Bicara’s 2026 Inducement Plan.

The grants were awarded to two new employees and totaled 207,150 stock options to purchase shares of Bicara’s common stock, with each share having a par value of $0.0001. The stock options were granted at an exercise price of $18.20 per share, which was the closing price of Bicara’s common stock as reported by Nasdaq on October 1, 2026.

Under the terms of the grants, one-fourth of the stock options vested on the first anniversary of the employees’ applicable start dates, with the remaining options vesting in 12 equal quarterly installments thereafter. The grants were granted outside of Bicara’s stockholder-approved equity incentive plans and were pursuant to Bicara’s 2026 Inducement Plan, which was adopted by Bicara’s board of directors in January 2026. The grants were approved by the compensation committee of Bicara’s board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4).

Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by reversing barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is currently being developed for head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types.